Crescita Therapeutics Inc.
CTX.TOTSXHealthcare● Active
$0.79
+$0.00(+0.00%)
Market Cap$14705011
P/E Ratio—
52W High$0.79
52W Low$0.4
Crescita Therapeutics Inc. (CTX.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTX.TO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $21.12M | $19.58M | $17.52M | $23.52M | $16.77M |
| Cost of Revenue | $10.74M | $9.97M | $7.16M | $10.34M | $6.75M |
| Gross Profit | $10.37M | $9.61M | $10.36M | $13.18M | $10.01M |
| Gross Margin %(computed) | 49.12% | 49.07% | 59.15% | 56.03% | 59.72% |
| Operating Expenses | |||||
| R&D Expenses | $0.57M | $0.65M | $0.70M | $0.61M | $0.63M |
| G&A Expenses | $0.00M | $10.81M | $10.12M | $0.00M | $0.00M |
| Total Operating Expenses | $11.39M | $12.82M | $12.32M | $12.65M | $10.73M |
| Operating Income | ($1.02M) | ($3.21M) | ($1.96M) | $0.73M | ($0.53M) |
| Operating Margin %(computed) | -4.84% | -16.42% | -11.16% | 3.11% | -3.15% |
| Interest Income | $0.33M | $0.50M | $0.51M | $0.26M | $0.18M |
| Interest Expense | $0.04M | $0.07M | $0.09M | $0.16M | $0.24M |
| Income Before Tax | ($0.08M) | ($2.76M) | ($1.53M) | $0.40M | ($1.01M) |
| Income Tax Expense | $0.01M | ($0.01M) | $0.46M | ($0.46M) | $0.10M |
| Net Income | ($0.09M) | ($2.75M) | ($1.99M) | $0.86M | ($1.10M) |
| Net Margin %(computed) | -0.44% | -14.04% | -11.33% | 3.66% | -6.59% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $-0.14 | $-0.10 | $0.04 | $-0.05 |
| Wtd Avg Shares | 18.85M | 19.27M | 20.26M | 20.69M | 20.76M |
| EBITDA | $0.48M | ($1.33M) | $0.04M | $2.09M | $0.60M |
| EBITDA Margin %(computed) | 2.27% | -6.81% | 0.26% | 8.88% | 3.57% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · M
Explore more Crescita Therapeutics Inc. data
About Crescita Therapeutics Inc. (CTX.TO) Income Statement
Crescita Therapeutics Inc. (CTX.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CTX.TO reported revenue of $0.02B, gross profit of $0.01B (gross margin 49.12%), and net income of ($0.00B) — a net profit margin of -0.44%.
Frequently asked questions
CTX.TO · 4 questionsCrescita Therapeutics Inc. (CTX.TO) reported revenue of $0.02B for 2025, up 7.9% year-over-year.
CTX.TO revenueCTX.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08